The Cancer Genetics and Genomics Program includes a group of outstanding investigators making Important and major contributions to the understanding of the molecular mechanisms underlying oncogenesis, the identification of genes that contribute to and confer susceptibility to cancer, and the translation of genomic signatures into clinical practice. This is a very Interactive and Integrated group of investigators that form a cohesive unit focused on the common goals of identifying genes involved in oncogenesis and their role in the development of human cancer. The activities of the program are organized into two specific areas of scientific focus that Include cancer genetics, with a focus on the Identification of genes that define risk of onset for disease;and cancer genomics, that involve programs applying technologies, particulariy DNA microarray analysis, to better understand the characteristics of tumors. These two aspects of the Program are tightly Integrated and exceedingly synergistic with work flowing between each to Influence the activities of the others. Indeed, we view a major strength of the Cancer Genetics and Genomics program to be the Interrelated activity - discoveries in work on oncogenic signaling pathways feeds the cancer genetics and genomics activities. Conversely, advances made in genomic applications to cancer outcomes have Impacted the study of oncogenic pathways. Indeed, this integration has led to the successful competition of a major NCI funded program in systems biology - the Integrated Cancer Biology Program - In which the focus of the program is tightly linked with activities of the Cancer Genetics and Genomics Program. Perhaps most importantly, studies in the program have led to the development of a series of genomic signatures for the prediction of lung cancer outcomes, chemotherapy sensitivity, and pathway activation tied to response to targeted therapeutics in which the science has formed the basis for translational studies in the form of multiple prospective clinical trials. The Program includes 21 members from 9 basic and clinical departments within Duke University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601809
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$15,560
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Adams, Rebecca N; Mosher, Catherine E; Blair, Cindy K et al. (2015) Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121:77-83
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6
Batinic-Haberle, Ines; Tovmasyan, Artak; Roberts, Emily R H et al. (2014) SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal 20:2372-415
Sachdeva, Mohit; Mito, Jeffrey K; Lee, Chang-Lung et al. (2014) MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest 124:4305-19
Tovmasyan, Artak; Carballal, Sebastian; Ghazaryan, Robert et al. (2014) Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem 53:11467-83
Azrad, Maria; Demark-Wahnefried, Wendy (2014) The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep 3:9-15
Blair, Cindy K; Madan-Swain, Avi; Locher, Julie L et al. (2013) Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol 52:1110-8
Mito, Jeffrey K; Min, Hooney D; Ma, Yan et al. (2013) Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 229:132-40
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 40:52-9
Hover, Bradley M; Loksztejn, Anna; Ribeiro, Anthony A et al. (2013) Identification of a cyclic nucleotide as a cryptic intermediate in molybdenum cofactor biosynthesis. J Am Chem Soc 135:7019-32

Showing the most recent 10 out of 161 publications